Premium
Tobramycin suppresses HUWE1 degradation to control MCL‐1 stability during tumour development
Author(s) -
He Jiabei,
Wu Sixian,
Li Xiaoliang,
Tang Li,
Chen Hanxiao,
Qin Lang,
Xie Jiang,
Lu Tao,
Xu Wenming
Publication year - 2020
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13335
Subject(s) - ubiquitin ligase , chemistry , ubiquitin , cell growth , cancer research , tobramycin , cell , microbiology and biotechnology , biochemistry , biology , gene , gentamicin , antibiotics
HUWE1 is an E3 ubiquitin ligase that is involved in cancer cell proliferation by regulating MCL‐1 stability. The HECT domain has been shown to be required for the ubiquitin ligase activity of HUWE1. To identify efficient drugs that impair the activity of HUWE1, and thus decrease MCL‐1 accumulation, we screened 2000 candidate compounds that might suppress HUWE1 activity. To evaluate these 2000 candidates, the HECT domain of HUWE1, which is the catalytic domain responsible for MCL1 ubiquitination, was selected as a conjugation site, and putative binding candidates were filtrated. Tobramycin emerged as one of the compounds that show efficient binding ability with the HECT domain of HUWE1. The surface plasmon resonance (SPR) results validated the specific binding of Tobramycin with the HECT domain. Subsequent analyses demonstrated its potential to inhibit cancer cell proliferation by binding to the HECT domain of HUWE1 and impeding the HUWE1‐mediated ubiquitination of MCL‐1. Consequently, the accumulation of MCL‐1 inhibited the proliferation of tumour cells, while the apoptosis rates were not significantly altered after Tobramycin treatment. In vitro experiments showed that Tobramycin could inhibit cell proliferation by regulating the G2/M transition in cancer cell models, including A549 and HeLaCaco2 cell lines. Our results indicated that Tobramycin could be a potential new probe to develop targeted therapies for the prevention or treatment of HUWE1‐overexpressing cancers.